Seres Therapeutics
MCRB
78 hedge funds and large institutions have $274M invested in Seres Therapeutics in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 13 closing their positions.
183% more call options, than puts
Call options by funds: $408K | Put options by funds: $144K
15% more capital invested
Capital invested by funds: $237M → $274M (+$36.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
0.07% less ownership
Funds ownership: 3.98% → 3.91% (-0.07%)
3% less funds holding
Funds holding: 80 → 78 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$7.02M |
| 2 |
BlackRock
New York
|
+$3.42M |
| 3 |
Millennium Management
New York
|
+$705K |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$565K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$415K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$6.08M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.45M |
| 3 |
Jennison Associates
New York
|
-$1.54M |
| 4 |
Renaissance Technologies
New York
|
-$1.19M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MCM
76
Manchester Capital Management
Manchester,
Vermont
| $1K | +$1.31K | +8 | New |
|
|
77
Capital World Investors
Los Angeles,
California
| – | -$6.08M | -41,391 | Closed |
|
|
78
Jennison Associates
New York
| – | -$1.54M | -10,510 | Closed |
|
|
O
79
OrbiMed
New York
| – | -$699K | -4,761 | Closed |
|
|
VEA
80
Virtus ETF Advisers
New York
| – | -$563K | -3,836 | Closed |
|
|
AA
81
ALPS Advisors
Denver,
Colorado
| – | -$399K | -2,718 | Closed |
|
|
ARTA
82
A.R.T. Advisors
New York
| – | -$337K | -2,298 | Closed |
|
|
ACI
83
AMP Capital Investors
Sydney,
Australia
| – | -$179K | -1,206 | Closed |
|
|
CS
84
Credit Suisse
Zurich,
Switzerland
| – | -$103K | -704 | Closed |
|
85
Russell Investments Group
London,
United Kingdom
| – | -$85K | -580 | Closed |
|
|
VF
86
Virtu Financial
New York
| – | -$78K | -533 | Closed |
|
87
Group One Trading
Chicago,
Illinois
| – | -$16.5K | -101 | Closed |
|
|
KF
88
Krilogy Financial
St. Louis,
Missouri
| – | -$3K | -20 | Closed |
|
89
US Bancorp
Minneapolis,
Minnesota
| – | -$1K | -6 | Closed |
|
90
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$327 | +2 | New |
|
MCRB Hedge Fund Activity: Q2 2018 in Review
78 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2018, worth a combined $274M — up 15% from $237M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of MCRB and 11 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 22 added.
The largest buyer was ARK Investment Management, adding an estimated $7.02M. The largest seller was Capital World Investors, exiting entirely with an estimated $6.08M sold.
- 78 institutional investors held Seres Therapeutics (MCRB) as of Q2 2018, down from 80 in Q1 2018.
- Funds reported $274M of Seres Therapeutics stock for Q2 2018, up 15% quarter-over-quarter.
- 11 funds opened new Seres Therapeutics positions in Q2 2018 and 13 closed out, a net change of -2 holders.
- The largest Seres Therapeutics buyer in Q2 2018 was ARK Investment Management, an estimated $7.02M added.
- The largest Seres Therapeutics seller in Q2 2018 was Capital World Investors, an estimated $6.08M sold.
Based on aggregated 13F filings for Q2 2018.